Filing Flows

Filing Flows › Veracyte (VCYT) › Next earnings date

Veracyte (VCYT) earnings: beat the estimate

Veracyte (VCYT) reported on Nov 4, 2026 and beat the EPS estimate: $0.51 against $0.41 (+24.5%). Revenue was $152M for Q3 2026, +15% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+24.5% vs estimate
Beat rate100%

The last report

Veracyte reported revenue of $152M for the third quarter 2026 (+15% Y/Y), net earnings $31.5M: Testing revenue $146M, Product revenue $4.6M, Biopharmaceutical and other revenue $709K. How it makes money → · Every quarter →

Veracyte: EPS against the estimate, last 5 reportsVeracyte: EPS against the estimate, last 5 reportsEstimateReported$0.32$0.51Nov 25$0.41$0.53Feb 26$0.33$0.52May 26$0.43$0.54Jul 26$0.41$0.51Nov 26
Latest (Nov 26): Estimate $0.41, Reported $0.51.
VCYT: the stock's move on each reportVCYT: the stock's move on each reportJul 30, 2026-16.9%May 5, 2026+23.1%Feb 25, 2026+8.6%Nov 4, 2025+26.3%

Veracyte's latest quarter

Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Veracyte beat earnings?

Veracyte (VCYT) reported on Nov 4, 2026 and beat the EPS estimate: $0.51 against $0.41 (+24.5%).

When does VCYT report earnings?

The next date is not set yet.

Does Veracyte usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.